What Альфадол Treats: Main Uses and Benefits

Альфадол is commonly used to help with conditions where the body’s ability to regulate essential minerals like calcium and phosphate is affected. The medication is applied across domains where additional symptomatic support is needed to manage these systemic imbalances.

Enhancing Bone Strength and Preventing Fractures

This medication is used for managing conditions that cause bones to become weak or soft, such as osteoporosis and osteomalacia. It contributes to improved comfort and stability by supporting skeletal health, and may assist with maintaining functional stability, particularly in conditions involving systemic or localized discomfort.

“This treatment is relevant for easing symptoms related to chronic mineral imbalance, which supports patients during difficult episodes of heightened discomfort.”

Correcting Mineral Imbalances and Parathyroid Disorders

Альфадол is commonly used to help with managing symptoms that arise from low blood calcium (hypocalcemia) or other significant mineral imbalances, often associated with parathyroid gland disorders. It may assist with managing symptoms related to increased neurological or muscular activity, such as spasms and cramps. This contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Muscle Spasms The medication may assist with reducing symptoms of increased neurological or muscular activity caused by low blood calcium levels.

Regulatory References

1. Health Canada Product Monograph for ONE-ALPHA

Who can and cannot use Альфадол?

The eligibility profile for Альфадол (Alfacalcidol) is strictly defined by regulatory documents, focusing on patient-specific conditions and physiological states.

Prohibited Use (Contraindications)

Use of this medicine is formally prohibited in patients who have pre-existing high calcium levels in the blood (hypercalcaemia), evidence of Vitamin D overdose, or clinical signs of metastatic calcification. It is also contraindicated in patients with known hypersensitivity to Alfacalcidol or specific inactive ingredients, such as in cases of hereditary fructose intolerance.

Restricted and Conditional Use

Certain populations must use the medicine under conditions of close clinical oversight. Use is not recommended for women who are pregnant or who are of child-bearing potential and not using contraception. For those who are breastfeeding, the infant must be closely monitored. Patients with existing renal impairment require consistent, vigilant monitoring of their calcium, phosphate, and creatinine levels. Caution is also advised for patients with granulomatous diseases like sarcoidosis or a history of kidney stones.

Established Eligible Populations

Use of the medicine is established across the full lifespan, including adults, adolescents, and older adults. Furthermore, it is documented for use in children and neonates for specific, labeled indications, provided all necessary monitoring protocols are strictly followed.

Interactions with other medicines and products

Official regulatory documents define Alfacalcidol’s interaction profile based on effects on mineral balance and drug exposure. These interactions often lead to specific restrictions and mandatory administration rules.

Documented Pharmacodynamic and PK Interactions

Interaction Type	Interacting Substances	Formal Regulatory Outcome
Conditional Contraindication	Digitalis Glycosides (e.g., Digoxin), Other Vitamin D Analogues	Contraindicated if hypercalcaemia is present; heightened risk of adverse effects.
Increased Metabolism (PK)	Enzyme-inducing Anticonvulsants (e.g., Phenytoin, Carbamazepine)	Increased metabolism of Alfacalcidol, which may require adjustment to maintain therapeutic effectiveness.
Additive Effect (PD)	Thiazide Diuretics, Calcium Supplements	Enhanced official risk of hypercalcaemia due to additive effects on calcium regulation.

---

Restrictions and Administration Rules

Co-administration with Magnesium-containing Antacids or Laxatives should be avoided due to the official risk of hypermagnesaemia. Furthermore, oral formulations may have their intestinal absorption impaired by substances like Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil. To mitigate this documented reduction in exposure, Alfacalcidol must be administered at least 1 hour before or 4 to 6 hours after these agents.

Regulatory labels also note that the alcohol (ethanol) excipient in the oral solution formulation is a specific consideration for use in children and patients with liver disease.

Альфадол (Alfacalcidol) functions as a prodrug, which undergoes rapid hepatic conversion via the 25-hydroxylase enzyme to its active metabolite, calcitriol (1,25-dihydroxyvitamin D3). This activation bypasses the renal 1alpha-hydroxylation step required for endogenous vitamin D.

Calcitriol acts as a ligand-agonist for the Vitamin D Receptor (VDR), a nuclear receptor present in target tissues, including the small intestine, kidneys, parathyroid glands, and bone. Upon binding, the VDR forms a heterodimer with the Retinoid X Receptor (RXR). This heterodimer translocates to the nucleus and binds to specific DNA sequences, known as Vitamin D Responsive Elements (VDREs), thereby modulating the transcription of target genes.

Downstream transcriptional regulation results in increased synthesis of proteins involved in calcium and phosphate transport.

System-level physiological modulation includes increased intestinal absorption of calcium and phosphate, enhanced renal tubular reabsorption of calcium, and direct regulation of bone mineralization and resorption processes. This collective action modulates systemic calcium and phosphate homeostasis and suppresses parathyroid hormone secretion.

Alfacalcidol is administered through oral and intravenous routes, with the specific formulation determined by the clinical context. Oral forms include soft capsules, typically available in 0.25 mcg, 0.5 mcg, and 1 mcg strengths, and an oral solution. The intravenous injection is reserved for specialized settings, such as hemodialysis.

The standard adult initial daily oral dose is 1 microgram per day for most indications, with the maintenance range generally falling between 0.25 and 2 micrograms per day. Dosage must be meticulously individualized and is typically adjusted in increments of 0.25 or 0.5 micrograms every two to four weeks, a protocol based on the narrow therapeutic window of the compound. The medicine is commonly taken once daily. However, for certain conditions like renal osteodystrophy in patients undergoing dialysis, a pulsed dosing schedule of two or three times per week may be implemented.

The timing of administration allows for flexibility, as the medicine may be taken with or without food. For consistent effects, patients are instructed to take the dose at the same time each day. Specific usage protocols apply to certain populations: children weighing less than 20 kg are typically started on a weight-based dose of 0.05 microgram/kg/day, while the starting dose for older adults may be limited to 0.5 microgram/day. If a dose is missed, the standard procedure is to take it as soon as remembered, but to skip the dose and continue the regular schedule if it is almost time for the next one; doses must never be doubled. A key procedural rule is to immediately stop the medicine if hypercalcemia develops, restarting at half the previous dose after calcium levels normalize.

Research Evidence / Overview of Studies for Альфадол

This section provides an overview of the clinical research that has examined Alfacalcidol, drawing solely from authoritative sources like randomized controlled trials (RCTs), meta-analyses, and regulatory reports. This is a summary of what the evidence suggests and does not offer any clinical advice or interpretation for personal use.

---

Evidence for Mineral Regulation in Chronic Kidney Disease

A significant body of research for Alfacalcidol has been conducted in adults with various stages of Chronic Kidney Disease (CKD), including patients requiring dialysis. These studies primarily involve Randomized Controlled Trials (RCTs) and meta-analyses that explore its application in managing mineral and bone disorders, such as secondary hyperparathyroidism (SHPT).

The research examined what changes in blood components related to mineral balance were recorded in studies of the medicine. The studies monitored key changes in biomarkers like Parathyroid Hormone (iPTH) levels, and shifts in serum calcium and serum phosphate were recorded. Trials reported patterns in iPTH levels and mineral balance that were measured during the study periods. Some research explored different administration schedules, examining the biomarker patterns measured in patients requiring dialysis. For bone health, studies have examined outcomes such as Bone Mineral Density (BMD) in pre-dialysis patients.

What remains uncertain: While research studies the patterns of iPTH and mineral levels in patients receiving the treatment, the long-term impact on major clinical outcomes remains an area of active discussion. Findings related to whether the medicine impacts outcomes such as all-cause mortality or cardiovascular events in CKD patients without high SHPT were mixed across large-scale studies.

---

Evidence for Managing Osteoporosis and Metabolic Bone Diseases

Alfacalcidol was studied in the context of bone disorders, including osteoporosis and specific forms of osteomalacia and rickets that can be resistant to standard Vitamin D therapy. These studies included RCTs comparing it to placebo, standard Vitamin D combined with calcium, or other bone-active medications, as well as systematic reviews.

Research monitored outcomes related to indicators of physical discomfort and measures of systemic functional imbalance. Studies examined whether a difference in the rate of vertebral and non-vertebral fractures was recorded in patients with osteoporosis. Furthermore, trials monitored changes in Bone Mineral Density (BMD) (especially in the lumbar spine) and shifts in bone turnover markers. For metabolic bone diseases like osteomalacia and rickets, evidence suggests that the research was relevant in trials assessing short-term or episodic symptom patterns, focusing on bone healing. Some findings in elderly populations described measured changes during the study period related to muscle function and fall frequency.

Key Studies & References

1. Public Assessment Report Scientific discussion Alfacalcidol ELC 0.25, 0.5 and 1 microgram soft capsules (alfacalcidol) NL
2. ONE-ALPHA® (Alfacalcidol) Product Monograph (Health Canada)
3. Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - StatPearls (General Clinical Guideline Reference)

Common questions about Альфадол (FAQ)

Q: How quickly should I expect to notice any effects from Альфадол?

According to official product information, the initial pharmacological effect of Alfacalcidol typically begins within 3 to 5 days after treatment is started. This measured time reflects when the drug's active form begins influencing mineral balance in the body. However, the time it takes to observe full therapeutic results may vary.

---

Q: Does Альфадол need to build up in the body to work fully?

Official product monographs indicate that while the immediate pharmacological action begins within a few days, the full normalization of blood calcium levels may take several months. This is due to the gradual adjustment of the body's mineral homeostasis system. Consistent use, as described in regulatory documents, is needed to work toward the full beneficial effects over time.

---

Q: Is Альфадол known to affect fertility in men or women?

Official regulatory documents state that no clinical studies have been conducted to determine the effects of Alfacalcidol on human fertility. However, pre-clinical studies, which involve animal testing, did not show evidence of any impact on fertility.

---

Q: Can I take Альфадол with herbal remedies?

Official warnings emphasize the importance of communicating with a healthcare professional about all substances being taken. This includes any herbal remedies or dietary supplements, as some ingredients may interact with Alfacalcidol and affect its action. Official guidance emphasizes the need to inform a healthcare professional of all substances being taken due to the potential for interactions.

---

Q: Does taking Альфадол affect my ability to drive or operate machinery?

Official regulatory documents indicate that Alfacalcidol has no or negligible direct effect on the ability to drive or use machines. However, patients should be aware that uncommon side effects, such as dizziness or a confusional state, have been reported during treatment. Patients who experience these effects should note this information.

---

Q: Will Альфадол change the results of any medical tests?

Official product information confirms that this medication can cause abnormal results in certain blood and urine tests. This occurs because the drug works by regulating calcium and phosphate levels in the body. Your healthcare professional monitors these changes and uses them to guide your treatment.

---

Q: Is the list of side effects in the official leaflet complete?

Official leaflets are required to list side effects based on their reported frequency, such as Common or Uncommon. Some effects are categorized as 'Not Known,' meaning their frequency cannot be accurately estimated from the available data at the time of publication. Regulatory bodies continuously monitor and update this information.

---

Q: How long does the effect of one dose of Альфадол last?

The pharmacological effects of Alfacalcidol are described in regulatory documents as relatively prolonged when compared to standard Vitamin D. This characteristic is linked to the way the active form of the medicine is utilized and regulated in the body.

---

Q: Is Альфадол a prescription-only medicine?

Yes, Alfacalcidol is available by prescription (Rx) only in major regulated markets worldwide. The medicine is for prescription use only because its dosage requires individual adjustment and routine monitoring by a healthcare professional.

---

Q: What if I accidentally took two doses of Альфадол?

Regulatory guidance indicates that if an overdose is suspected, contacting a healthcare professional or hospital emergency department is the appropriate protocol, even in the absence of symptoms. Taking excessive amounts of Alfacalcidol may lead to dangerously high levels of calcium or phosphate in the blood. Official guidance strictly advises against ever doubling a dose.

---

Q: Is it normal to feel tired after starting Альфадол?

Official regulatory documents list fatigue (tiredness) or asthenia (weakness) as an Uncommon side effect reported by some users. Feeling tired can also be a symptom of hypercalcaemia, which is high blood calcium. This symptom, if persistent or severe, should be discussed with the prescribing healthcare professional.

---

Q: Can I split or crush Альфадол tablets?

Official patient information generally instructs that soft capsules and tablets should be swallowed whole with liquid. Patients are typically advised not to crush, chew, break, or open the capsules or tablets. Altering the form of the medicine can change how it is absorbed by the body.

---

Q: Will Альфадол interact with my over-the-counter cold medicine?

Specific interactions with every component of over-the-counter cold medicines are not routinely itemized in official labels. However, regulatory standards require you to inform your healthcare professional about all current medicines, as certain interactions are possible.

---

Q: Is there a generic version of Альфадол available?

Yes, Alfacalcidol is the generic (non-proprietary) name for the active ingredient itself. Generic products containing Alfacalcidol are licensed and available in many regulated markets under various different brand names.

---

Q: Is Альфадол widely used outside of my country?

Official documentation indicates that Alfacalcidol is licensed and used in many major regulated territories worldwide, including regions like the European Union, Canada, and Japan. It is used for approved indications related to the management of calcium and phosphate metabolism.

How to Store and Dispose of Alfacalcidol (Альфадол)

Storage and disposal requirements for Alfacalcidol are defined by official regulatory labeling to ensure product stability and safety. Mandatory conditions vary based on the pharmaceutical form.

---

Storage Requirements

Formulation	Required Storage Condition
Capsules	Do not store above 25°C. Keep in a cool, dry place.
Oral Solution (Drops)	Must be stored in a refrigerator (2°C to 8°C). Do not freeze.

All formulations must be protected from light and kept in their original outer carton.

Disposal and Safety

• The oral solution must be discarded 4 months after opening.
• It is mandatory to keep the medicine out of the sight and reach of children.
• Disposal instructions forbid throwing unused or expired medicine into wastewater or household waste. Patients must ask a pharmacist for the proper disposal procedure.